MedicaidPrior AuthMedium impact
Vectibix (panitumumab) (New)
Humana·IN · Oncology, Hematology·Medicaid
Effective date
Feb 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicaid Indiana has implemented a new prior authorization policy for Vectibix (panitumumab), an IV cancer treatment for metastatic colorectal cancer. This policy requires specific criteria including RAS mutation testing, prior chemotherapy treatments, and appropriate combination therapies before approval.
Action Required
Before February 1, 2026: Billing team must implement prior authorization requirements for Vectibix (panitumumab) IV infusions for Humana Medicaid Indiana members. Ensure providers document advanced/metastatic colorectal cancer diagnosis, wild-type RAS mutation status (or KRAS G12C mutation), prior chemotherapy treatments, and appropriate combination therapy plans. Update encounter forms to include required clinical criteria. Claims will be denied without proper prior authorization.